What is Caretrust's earnings per share (EPS)?

Caretrust (CTRE) reported diluted earnings per share of $1.57 for fiscal year 2025. This represents a 96.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Caretrust Financials

CTRE

Trailing 12 months to June 30, 2026

Revenue $571.4M +53.0% YoY

Net Income $355.4M +61.6% YoY

EPS (Diluted) $1.60 +32.2% YoY

Free Cash Flow Not reported for the trailing 12 months

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Caretrust (CTRE) reported $571.4M in revenue over the twelve months to Jun 30, 2026, up 53.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CTRE FY2025 2026-05-07

CareTrust’s core mechanic is asset-base expansion, funded so that cash generation scales faster than balance-sheet risk without overwhelming leverage.

From FY2023 to FY2025, total assets rose from $2.08B to $5.15B. Yet debt-to-equity was only 0.2x in FY2025 and combined investing outflows across FY2024-FY2025 were about $2.97B, so the portfolio expansion was financed mainly with equity capital and internally generated cash, not with debt layered onto the balance sheet; the jump in shares outstanding supports that reading.

The cash conversion pattern is stronger than headline earnings suggest: FY2025 operating cash flow reached $394M versus net income of $321M. Even FY2022’s loss did not interrupt positive operating cash flow, which implies non-cash charges and portfolio accounting make reported profit on the income statement more volatile than the cash actually available to support dividends and reinvestment.

The interest burden stayed manageable because FY2025 interest expense was $43.7M against $394M of operating cash flow. And with receivables at just $10.4M, working capital does not appear to be the bottleneck; cash is tied up in long-lived assets rather than in slow customer collections or inventory.

Financial Health Signals

Financial Health Score 58/100

Scored as: REITs peer group

Scored against REITs for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Caretrust's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

FFO Margin

FFO Growth

Leverage

Not available for Caretrust, and counted as zero in the overall score.

Interest Cov.

Not available for Caretrust, and counted as zero in the overall score.

AFFO Margin

Dividend Cov.

Piotroski F-Score Partial

5/7

Caretrust passes 5 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.23x

For every $1 of reported earnings, Caretrust generates $1.23 in operating cash flow ($394.0M OCF vs $320.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$476.4M

YoY+60.8%

5Y CAGR+21.7%

10Y CAGR+20.3%

Caretrust generated $476.4M in revenue in fiscal year 2025. This represents an increase of 60.8% from the prior year.

Net Income

$320.5M

YoY+156.3%

5Y CAGR+31.7%

10Y CAGR+41.4%

Caretrust reported $320.5M in net income in fiscal year 2025. This represents an increase of 156.3% from the prior year.

EPS (Diluted)

$1.57

YoY+96.3%

5Y CAGR+13.1%

10Y CAGR+19.7%

Caretrust earned $1.57 per diluted share (EPS) in fiscal year 2025. This represents an increase of 96.3% from the prior year.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$198.0M

YoY-7.4%

5Y CAGR+59.9%

10Y CAGR+33.0%

Caretrust held $198.0M in cash against $894.2M in long-term debt as of fiscal year 2025.

Dividends Per Share

$1.34

YoY+15.5%

5Y CAGR+6.0%

10Y CAGR+7.7%

Caretrust paid $1.34 per share in dividends in fiscal year 2025. This represents an increase of 15.5% from the prior year.

Shares Outstanding

223M

YoY+19.0%

5Y CAGR+18.4%

10Y CAGR+16.6%

Caretrust had 223M shares outstanding in fiscal year 2025. This represents an increase of 19.0% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Margins & Returns

Net Margin

67.3%

YoY+25.1pp

5Y CAGR+21.9pp

10Y CAGR+53.9pp

Caretrust's net profit margin was 67.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 25.1 percentage points from the prior year.

Return on Equity

7.9%

YoY+3.6pp

5Y CAGR-0.9pp

10Y CAGR+4.1pp

Caretrust's ROE was 7.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.6 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Capital Allocation

None of these metrics is reported for fiscal year 2025.

CTRE Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CTRE quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Revenue	$571.4M	$476.4M+60.8%	$296.3M+36.1%	$217.8M+11.0%	$196.1M+2.0%	$192.4M+7.9%	$178.3M+9.1%	$163.4M+4.1%	$156.9M+18.0%	$133.0M+27.0%	$104.7M+39.7%	$75.0M+27.3%	$58.9M+20.7%	$48.8M+16.0%	$42.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$1.9M-35.5%	$2.9M-2.2%	$3.0M+8.5%	$2.7M+7.2%	$2.5M	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$192.4M+9.0%	$176.5M+9.9%	$160.5M+4.2%	$154.0M+18.2%	$130.2M+27.5%	$102.1M	N/A	N/A	N/A	N/A
SG&A Expenses	$61.0M	$52.5M+81.4%	$28.9M+32.6%	$21.8M+8.1%	$20.2M-25.0%	$26.9M+64.9%	$16.3M+7.5%	$15.2M+20.7%	$12.6M+12.9%	$11.1M+19.6%	$9.3M+21.5%	$7.7M-31.1%	$11.1M+104.1%	$5.4M+204.4%	$1.8M
Interest Expense	$50.6M	$43.7M+44.2%	$30.3M-25.9%	$40.9M+36.2%	$30.0M+26.7%	$23.7M+0.1%	$23.7M-15.9%	$28.1M+1.0%	$27.9M+15.1%	$24.2M+5.8%	$22.9M-4.9%	$24.0M+11.2%	$21.6M+71.0%	$12.6M+3.6%	$12.2M
Income Tax	$8.8M	$5.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$123K+0.8%	$122K
Net Income	$355.4M	$320.5M+156.3%	$125.1M+132.8%	$53.7M+815.9%	-$7.5M-110.4%	$72.0M-11.0%	$80.9M+74.4%	$46.4M-20.0%	$57.9M+123.9%	$25.9M-11.9%	$29.4M+192.5%	$10.0M+223.2%	-$8.1M-1961.5%	-$395K-459.1%	$110K
EPS (Diluted)	$1.60	$1.57+96.3%	$0.80+60.0%	$0.50+725.0%	-$0.08-110.8%	$0.74-12.9%	$0.85+73.5%	$0.49-31.9%	$0.72+105.7%	$0.35-32.7%	$0.52+100.0%	$0.26	-$0.36-1700.0%	-$0.02	$0.00

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$161.3M+13.0%	$142.8M+5.9%	$134.9M+1.8%	$132.4M+17.8%	$112.5M+16.4%	$96.6M+11.1%	$86.9M+12.4%	$77.4M
SG&A Expenses	$15.8M+10.0%	$14.3M-7.3%	$15.5M+0.3%	$15.4M+22.9%	$12.5M+39.1%	$9.0M-2.8%	$9.3M+39.4%	$6.7M
Interest Expense	$15.3M+36.3%	$11.2M-1.2%	$11.4M-9.9%	$12.6M-3.2%	$13.0M+95.5%	$6.7M+30.2%	$5.1M-38.1%	$8.3M
Income Tax	$2.5M+11.6%	$2.3M+19.9%	$1.9M-8.8%	$2.1M+101.7%	$1.0M	$0	N/A	$0
Net Income	$89.0M+11.0%	$80.2M-27.9%	$111.3M+48.6%	$74.9M+9.3%	$68.5M+4.2%	$65.8M+26.2%	$52.1M+55.9%	$33.4M
EPS (Diluted)	$0.38+5.6%	$0.36-29.4%	$0.51+45.7%	$0.350.0%	$0.350.0%	$0.35+16.7%	$0.30+42.9%	$0.21

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, Operating Income.

CTRE Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CTRE quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Total Assets	$5.1B+49.8%	$3.4B+64.9%	$2.1B+28.6%	$1.6B-1.2%	$1.6B+9.1%	$1.5B-1.0%	$1.5B+17.6%	$1.3B+9.0%	$1.2B+28.1%	$925.4M+37.5%	$673.2M+41.7%	$475.1M+10.4%	$430.5M	N/A
Cash & Equivalents	$198.0M-7.4%	$213.8M-27.4%	$294.4M+2134.4%	$13.2M-33.8%	$19.9M+5.2%	$18.9M-6.9%	$20.3M-44.8%	$36.8M+432.5%	$6.9M-7.9%	$7.5M-34.6%	$11.5M-54.7%	$25.3M+2729.1%	$895K+21.8%	$735K
Accounts Receivable	$10.4M+783.1%	$1.2M+197.2%	$395K-5.0%	$416K-82.8%	$2.4M+32.6%	$1.8M-29.1%	$2.6M-77.4%	$11.4M+116.7%	$5.3M-10.9%	$5.9M+151.8%	$2.3M+2.2%	$2.3M+11355.0%	$20K	N/A
Total Liabilities	$1.1B+114.6%	$507.6M-23.8%	$666.1M-13.6%	$771.4M+6.4%	$725.1M+23.0%	$589.4M-0.3%	$591.3M+12.9%	$523.5M-11.3%	$590.4M+24.8%	$472.9M+15.1%	$410.9M+13.6%	$361.7M+35.1%	$267.8M	N/A
Long-Term Debt	$894.2M+125.3%	$396.9M-33.4%	$595.6M-17.2%	$719.5M+6.8%	$673.4M+23.4%	$545.6M-1.6%	$554.6M+13.2%	$489.8M-12.4%	$558.9M+24.3%	$449.7M+14.2%	$393.9M+12.3%	$350.8M+35.3%	$259.3M	N/A
Total Equity	$4.0B+38.7%	$2.9B+105.3%	$1.4B+66.8%	$849.4M-7.2%	$915.8M+0.2%	$914.1M-1.4%	$927.6M+20.7%	$768.2M+29.2%	$594.6M+31.4%	$452.4M+72.5%	$262.3M+131.2%	$113.5M-30.3%	$162.7M-11.8%	$184.5M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$5.9B+13.2%	$5.2B+1.7%	$5.1B+1.2%	$5.1B+9.3%	$4.7B+19.9%	$3.9B+13.0%	$3.4B+17.7%	$2.9B
Cash & Equivalents	$47.6M-78.7%	$223.2M+12.7%	$198.0M-72.2%	$712.5M+132.8%	$306.1M+1054.5%	$26.5M-87.6%	$213.8M-43.3%	$377.1M
Accounts Receivable	$18.0M+24.2%	$14.5M+39.5%	$10.4M+40.3%	$7.4M+175.0%	$2.7M+37.5%	$2.0M+66.4%	$1.2M+33.3%	$881K
Total Liabilities	$1.4B+30.7%	$1.1B-0.6%	$1.1B+1.7%	$1.1B-19.5%	$1.3B+42.2%	$936.3M+84.4%	$507.6M+2.3%	$496.1M
Long-Term Debt	$1.2B+34.7%	$894.6M0.0%	$894.2M0.0%	$893.8M-22.6%	$1.2B+40.5%	$822.1M+107.1%	$396.9M+0.1%	$396.7M
Total Equity	$4.5B+8.7%	$4.1B+2.4%	$4.0B+1.0%	$4.0B+21.0%	$3.3B+12.7%	$2.9B+0.6%	$2.9B+20.1%	$2.4B

Not reported in any period shown, so not listed: Current Assets, Inventory, Goodwill, Current Liabilities, Retained Earnings.

CTRE Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CTRE quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Operating Cash Flow	$447.0M	$394.0M+61.3%	$244.3M+57.8%	$154.8M+7.2%	$144.4M-7.9%	$156.9M+7.6%	$145.7M+15.4%	$126.3M+27.1%	$99.4M+11.9%	$88.8M+37.8%	$64.4M+60.1%	$40.3M+83.8%	$21.9M-17.7%	$26.6M+10.3%	$24.1M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$2.9M+64.8%	$1.8M+342.2%	$403K+166.9%	$151K-45.3%	$276K-98.6%	$19.3M-3.3%	$19.9M+0.9%	$19.8M
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$123.4M+26.4%	$97.6M+10.4%	$88.4M+37.5%	$64.3M+60.8%	$40.0M+1419.5%	$2.6M-60.7%	$6.7M+53.0%	$4.4M
Investing Cash Flow	-$1.6B	-$1.5B+3.5%	-$1.5B-465.2%	-$267.8M-110.2%	-$127.4M+33.9%	-$192.6M-363.3%	-$41.6M+86.8%	-$316.0M-174.6%	-$115.1M+62.0%	-$302.6M-6.3%	-$284.6M-21.3%	-$234.6M-337.8%	-$53.6M+2.1%	-$54.7M	N/A
Financing Cash Flow	$923.4M	$1.1B-11.6%	$1.2B+201.5%	$394.3M+1761.5%	-$23.7M-164.6%	$36.7M+134.8%	-$105.6M-160.9%	$173.2M+280.0%	$45.6M-78.6%	$213.2M-1.4%	$216.2M+19.8%	$180.5M+221.7%	$56.1M+98.6%	$28.3M	N/A
Dividends Paid	$305.2M	$259.3M+50.6%	$172.2M+49.1%	$115.5M+8.8%	$106.1M+5.3%	$100.8M+8.2%	$93.2M+15.6%	$80.6M+28.0%	$63.0M+19.8%	$52.6M+41.1%	$37.3M+71.0%	$21.8M-34.0%	$33.0M	$0	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$134.7M+49.1%	$90.4M-25.3%	$121.0M+19.9%	$100.9M+0.1%	$100.8M+41.2%	$71.4M-5.1%	$75.2M+11.8%	$67.2M
Investing Cash Flow	-$885.4M-741.3%	-$105.2M+81.2%	-$560.3M-639.7%	-$75.7M+90.4%	-$789.4M-2098.3%	-$35.9M+94.8%	-$685.6M-90.7%	-$359.4M
Financing Cash Flow	$576.9M+1323.3%	$40.5M+153.8%	-$75.3M-119.7%	$381.2M+5.4%	$361.8M-5.6%	$383.2M-14.3%	$447.1M+156.7%	$174.2M
Dividends Paid	$88.5M+18.2%	$74.8M0.0%	$74.8M+11.5%	$67.1M+6.4%	$63.1M+15.9%	$54.4M+9.4%	$49.7M+11.2%	$44.7M

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Share Buybacks.

CTRE Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CTRE quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Gross Margin	N/A	N/A	N/A	N/A	100.0%+1.0pp	99.0%+0.7pp	98.2%+0.1pp	98.1%+0.2pp	97.9%+0.4pp	97.6%	N/A	N/A	N/A	N/A
Net Margin	67.3%+25.1pp	42.2%+17.5pp	24.7%+28.5pp	-3.8%-41.3pp	37.4%-7.9pp	45.4%+17.0pp	28.4%-8.5pp	36.9%+17.4pp	19.5%-8.6pp	28.0%+14.6pp	13.4%+27.2pp	-13.8%-13.0pp	-0.8%-1.1pp	0.3%
Return on Equity	7.9%+3.6pp	4.3%+0.5pp	3.8%+4.7pp	-0.9%-8.7pp	7.9%-1.0pp	8.8%+3.8pp	5.0%-2.5pp	7.5%+3.2pp	4.3%-2.1pp	6.5%+2.7pp	3.8%+11.0pp	-7.2%-6.9pp	-0.2%-0.3pp	0.1%
Return on Assets	6.2%+2.6pp	3.6%+1.1pp	2.6%+3.0pp	-0.5%-4.9pp	4.4%-1.0pp	5.4%+2.3pp	3.0%-1.4pp	4.5%+2.3pp	2.2%-1.0pp	3.2%+1.7pp	1.5%+3.2pp	-1.7%-1.6pp	-0.1%	N/A
Debt-to-Equity	0.22+0.1x	0.14-0.3x	0.42-0.4x	0.85+0.1x	0.74+0.1x	0.600.0x	0.600.0x	0.64-0.3x	0.94-0.1x	0.99-0.5x	1.50-1.6x	3.09+1.5x	1.59	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	75.5%+13.3pp	62.2%-4.3pp	66.5%+5.1pp	61.4%+8.1pp	53.3%+48.9pp	4.5%-9.3pp	13.7%+3.3pp	10.4%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Net Margin	55.2%-1.0pp	56.2%-26.3pp	82.5%+26.0pp	56.5%-4.4pp	61.0%-7.2pp	68.1%+8.1pp	60.0%+16.7pp	43.2%
Return on Equity	2.0%0.0pp	1.9%-0.8pp	2.8%+0.9pp	1.9%-0.2pp	2.1%-0.2pp	2.3%+0.5pp	1.8%+0.4pp	1.4%
Return on Assets	1.5%0.0pp	1.5%-0.6pp	2.2%+0.7pp	1.5%0.0pp	1.5%-0.2pp	1.7%+0.2pp	1.5%+0.4pp	1.1%
Debt-to-Equity	0.27+0.1x	0.220.0x	0.220.0x	0.22-0.1x	0.35+0.1x	0.28+0.1x	0.140.0x	0.16

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Current Ratio, FCF Margin.

Similar Companies

AMERICAN HEALTHCARE REIT INC AHR

$12.5B

Healthcare Tr Amer Inc HR

$6.6B

Sabra Health Care Reit Inc SBRA

$5.4B

Medical Prop MPW

$3.0B

National Health Investors NHI

$3.6B

Where Caretrust Ranks

Frequently Asked Questions

What is Caretrust's annual revenue?

Caretrust (CTRE) reported $476.4M in total revenue for fiscal year 2025. This represents a 60.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Caretrust's revenue growing?

Caretrust (CTRE) revenue grew by 60.8% year-over-year, from $296.3M to $476.4M in fiscal year 2025.

Is Caretrust profitable?

Yes, Caretrust (CTRE) reported a net income of $320.5M in fiscal year 2025, with a net profit margin of 67.3%.

How much debt does Caretrust have?

As of fiscal year 2025, Caretrust (CTRE) had $198.0M in cash and equivalents against $894.2M in long-term debt.

What is Caretrust's net profit margin?

Caretrust (CTRE) had a net profit margin of 67.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Caretrust pay dividends?

Yes, Caretrust (CTRE) paid $1.34 per share in dividends during fiscal year 2025.

What is Caretrust's return on equity (ROE)?

Caretrust (CTRE) has a return on equity of 7.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Caretrust's operating cash flow?

Caretrust (CTRE) generated $394.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Caretrust's total assets?

Caretrust (CTRE) had $5.1B in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Caretrust have outstanding?

Caretrust (CTRE) had 223M shares outstanding as of fiscal year 2025.

What is Caretrust's debt-to-equity ratio?

Caretrust (CTRE) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Caretrust's return on assets (ROA)?

Caretrust (CTRE) had a return on assets of 6.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Caretrust's Piotroski F-Score?

Caretrust (CTRE) has a Piotroski F-Score of 5 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Caretrust's earnings high quality?

Caretrust (CTRE) has an earnings quality ratio of 1.23x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Caretrust?

Caretrust (CTRE) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its REITs peer group. The score is a 0-100 composite of six dimensions (FFO Margin, FFO Growth, Leverage, Interest Cov., AFFO Margin, Dividend Cov.), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.